Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2004 2
2005 8
2006 5
2007 2
2008 6
2010 2
2011 2
2012 1
2016 1
2018 1
2019 1
2020 1
2021 3
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
Haab F, Stewart L, Dwyer P. Haab F, et al. Eur Urol. 2004 Apr;45(4):420-9; discussion 429. doi: 10.1016/j.eururo.2004.01.008. Eur Urol. 2004. PMID: 15041104 Review.
At this time the number of incontinence episodes per week was reduced from baseline by 67.7% with darifenacin 7.5 mg and 72.8% with darifenacin 15 mg compared with 55.9% with placebo (p=0.010 and p=0.017, respectively, versus placebo). ...However, no patients withdr …
At this time the number of incontinence episodes per week was reduced from baseline by 67.7% with darifenacin 7.5 mg and 72.8% with …
Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study.
Haab F, Corcos J, Siami P, Glavind K, Dwyer P, Steel M, Kawakami F, Lheritier K, Steers WD. Haab F, et al. BJU Int. 2006 Nov;98(5):1025-32. doi: 10.1111/j.1464-410X.2006.06439.x. Epub 2006 Jul 28. BJU Int. 2006. PMID: 16879437 Clinical Trial.
PATIENTS AND METHODS: Patients entering the extension received darifenacin 7.5 mg once daily for 2 weeks, after which a voluntary increase in dose to 15 mg was permitted. ...As such, darifenacin represents a valuable therapeutic option for OAB....
PATIENTS AND METHODS: Patients entering the extension received darifenacin 7.5 mg once daily for 2 weeks, after which a voluntary inc …
Neurological safety and efficacy of darifenacin and mirabegron for the treatment of overactive bladder in patients with history of cerebrovascular accident: A prospective study.
Vasudeva P, Kumar A, Yadav S, Kumar N, Chaudhry N, Prasad V, Nagendra Rao S, Yadav P, Patel S. Vasudeva P, et al. Neurourol Urodyn. 2021 Nov;40(8):2041-2047. doi: 10.1002/nau.24793. Epub 2021 Sep 13. Neurourol Urodyn. 2021. PMID: 34516666 Clinical Trial.
OBJECTIVES: To evaluate the neurological safety and clinical efficacy of darifenacin and mirabegron in patients with a history of cerebrovascular accident (CVA) who had overactive bladder (OAB) symptoms. ...On intergroup comparison, the mean change in bladder diary paramet …
OBJECTIVES: To evaluate the neurological safety and clinical efficacy of darifenacin and mirabegron in patients with a history of cer …
Darifenacin Versus Parasacral Transcutaneous Electric Nerve stimulation for overactive bladder syndrome in patients infected with Human T-Lymphotropic Virus 1 - randomized open clinical trial.
de Oliveira TSS, C JA Neto, Oliveira CJV, Castro NM, Carvalho EM. de Oliveira TSS, et al. Int Braz J Urol. 2025 Jul-Aug;51(4):e20240567. doi: 10.1590/S1677-5538.IBJU.2024.0567. Int Braz J Urol. 2025. PMID: 40327517 Free PMC article. Clinical Trial.
However, 5 (23.8%) of the patients in the group treated with darifenacin abandoned the therapy, while only 1 patient (4,8%) stopped PTENS. CONCLUSIONS: Both protocols used in this study were effective in treating OAB syndrome and reducing OABSS. However, therapy abandonmen …
However, 5 (23.8%) of the patients in the group treated with darifenacin abandoned the therapy, while only 1 patient (4,8%) stopped P …
A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder.
Chancellor MB, Kianifard F, Beamer E, Mongay L, Ebinger U, Hicks G, Delconte A. Chancellor MB, et al. Int J Clin Pract. 2008 Apr;62(4):606-13. doi: 10.1111/j.1742-1241.2008.01714.x. Int J Clin Pract. 2008. PMID: 18324952 Free PMC article. Clinical Trial.
RESULTS: Of 592 patients screened, 395 were randomised, 190 to darifenacin alone and 205 to darifenacin + BMP. At baseline, the majority of subjects were dry (mean 2.8 and three UUI episodes per day in the darifenacin and darifenacin + BMP groups respe …
RESULTS: Of 592 patients screened, 395 were randomised, 190 to darifenacin alone and 205 to darifenacin + BMP. At baseline, th …
QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder.
Serra DB, Affrime MB, Bedigian MP, Greig G, Milosavljev S, Skerjanec A, Wang Y. Serra DB, et al. J Clin Pharmacol. 2005 Sep;45(9):1038-47. doi: 10.1177/0091270005279010. J Clin Pharmacol. 2005. PMID: 16100298 Clinical Trial.
There was no significant increase in QTcF interval with darifenacin treatment compared with placebo. Mean changes from baseline at pharmacokinetic Tmax versus placebo were -0.4 and -2.2 milliseconds in the darifenacin 15 mg and 75 mg groups, respectively, compared w …
There was no significant increase in QTcF interval with darifenacin treatment compared with placebo. Mean changes from baseline at ph …
Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder.
Zinner N, Tuttle J, Marks L. Zinner N, et al. World J Urol. 2005 Sep;23(4):248-52. doi: 10.1007/s00345-005-0507-3. Epub 2005 Nov 8. World J Urol. 2005. PMID: 16096831 Clinical Trial.
Darifenacin and oxybutynin significantly reduced incontinence episodes, and the number/severity of urgency episodes (all P<0.05 versus placebo). Improvements in OAB symptoms with darifenacin were dose-dependent. Dry mouth was less common with darifenacin 1 …
Darifenacin and oxybutynin significantly reduced incontinence episodes, and the number/severity of urgency episodes (all P<0.05 ve …
Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR. Bayés M, et al. Methods Find Exp Clin Pharmacol. 2004 Dec;26(10):801-27. Methods Find Exp Clin Pharmacol. 2004. PMID: 15672123 Clinical Trial.
This issue focuses on the following selection of drugs: Abetimus sodium, ademetionine, agalsidase alfa, agalsidase beta, alemtuzumab, alfimeprase, AMG-162, androgel, anidulafungin, antigastrin therapeutic vaccine, aripiprazole, atomoxetine hydrochloride; Bazedoxifene acetate, bev …
This issue focuses on the following selection of drugs: Abetimus sodium, ademetionine, agalsidase alfa, agalsidase beta, alemtuzumab, alfime …
Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR. Bayes M, et al. Methods Find Exp Clin Pharmacol. 2006 Jul-Aug;28(6):379-412. Methods Find Exp Clin Pharmacol. 2006. PMID: 16894408 Clinical Trial.
This issue focuses on the following selection of drugs:(R)-Flurbiprofen, 90Yttrium-DOTA-huJ591; ABT-510, ACP-103, Ad5-FGF4, adalimumab, ademetionine, AG-7352, alemtuzumab, Amb a 1 ISS-DNA, anakinra, apaziquone, aprepitant, aripiprazole, atazanavir sulfate; BAL-8557, bevacizumab, …
This issue focuses on the following selection of drugs:(R)-Flurbiprofen, 90Yttrium-DOTA-huJ591; ABT-510, ACP-103, Ad5-FGF4, adalimumab, adem …
Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects.
Kay G, Crook T, Rekeda L, Lima R, Ebinger U, Arguinzoniz M, Steel M. Kay G, et al. Eur Urol. 2006 Aug;50(2):317-26. doi: 10.1016/j.eururo.2006.03.057. Epub 2006 Apr 19. Eur Urol. 2006. PMID: 16687205 Clinical Trial.
OBJECTIVES: To investigate the effects of darifenacin controlled-release (CR) and oxybutynin extended-release (ER) on cognitive function (particularly memory) in older subjects. METHODS: Healthy subjects (n=150) >/=60 years were randomised to darifenacin, oxybuty …
OBJECTIVES: To investigate the effects of darifenacin controlled-release (CR) and oxybutynin extended-release (ER) on cognitive funct …
34 results